Skip to main content

Table 2 EGFR, MET, p-MET, HGF protein expression levels and MET gene amplification in the complete series

From: Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

Expression levels

test Group

Control group

P value

n

%

n

%

EGFR

    

0.053

 Low

0

0.0

2

8.3

 

 Medium

2

6.1

3

12.5

 

 High

25

75.7

19

79.2

 

 ND

6

18.2

   

MET

    

0.066

 Low

8

24.2

16

66.7

 

 Medium

16

48.5

5

20.8

 

 High

9

27.3

3

12.5

 

p-MET

    

0.060

 Low

27

81.8

20

83.3

 

 Medium

4

12.1

4

16.7

 

 High

2

6.1

0

0.0

 

MET gene

    

0.092

 Yes

17

51.5

7

29.2

 

 No

16

48.5

17

70.8

 

HGF

    

0.369

 Low

9

27.3

11

45.8

 

 Medium

17

51.5

10

41.7

 

 High

7

21.2

3

12.5

 
  1. Different ranges included those cases with low (0–33 %), medium (34–66 %), or high (67–100 %) IHC expression levels determined as a percentage of the Hscore